In an interview, Saad Z. Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated multiple myeloma.

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

In closing, the panel of experienced multiple myeloma care partners offers a powerful, unified message of hope and actionable advice.

The MarketWatch News Department was not involved in the creation of this content. STUDIO CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed ...

STUDIO CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of Directors. After going ...

The syndrome of inappropriate antidiuresis (SIAD) has been associated with various diseases. However, to our knowledge, only a few studies have reported multiple myeloma (MM) as a potential cause of ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...

D-VRd is the first anti-CD38 antibody-based regimen approved for all newly diagnosed multiple myeloma patients, regardless of transplant eligibility. The CEPHEUS trial demonstrated significant ...